The flu is now widespread in all but six states. The CDC reported that flu activity is still widespread and as usual it's hitting the elderly particularly hard. Dr. Jon LaPook reports on the record set by this year's flu season.
Video (2:08)
Elderly hard-hit by tough flu season - YouTube
Saturday, January 31, 2015
White House urges vaccinations amid measles threat | TheHill
Parents should listen to public health officials who encourage vaccination, the White House said Friday amid reports that hundreds of people in Arizona may have been exposed to the measles virus.
“Being guided by the science in matters like this is typically the right approach,” White House press secretary Josh Earnest said, adding that research “certainly” indicates parents should vaccinate their children.
White House urges vaccinations amid measles threat | TheHill
“Being guided by the science in matters like this is typically the right approach,” White House press secretary Josh Earnest said, adding that research “certainly” indicates parents should vaccinate their children.
White House urges vaccinations amid measles threat | TheHill
Thursday, January 29, 2015
Measles outbreak quickly spreads to other states - YouTube
As the measles outbreak grows, so is the pressure from parents telling other parents to vaccinate their children. Ben Tracy spoke to one family who says a lack of vaccinations is putting their already sick child at risk.
Video (2:36)
Measles outbreak quickly spreads to other states - YouTube
Video (2:36)
Measles outbreak quickly spreads to other states - YouTube
Ahead of Print -Rickettsia rickettsii in Amblyomma patinoi Ticks, Colombia - Volume 21, Number 3—March 2015 - Emerging Infectious Disease journal - CDC
Don't Let Bacteria Score a Touchdown at Your Super Bowl Party
From USDA:
Super Bowl Infographic, "Four Steps to Food Safety". Click to enlarge.
The Super Bowl is one of the most popular sporting events in the United States and the second largest food consumption day. This means there are many opportunities for Americans to come into contact with some nasty bacteria that can cause food poisoning.
According to the National Restaurant Association, more than 48 million Americans will order takeout or delivery during the game. In 2014, the National Chicken Council estimated that 1.25 billion chicken wings were consumed Super Bowl weekend. To promote proper food handling, the U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) is issuing safety recommendations to explain how you can keep your Super Bowl food both safe and delicious.
Hosts and guests need to have the proper defense in place to keep bacteria on the sideline and prevent foodborne illness from scoring a touchdown at their Super Bowl party.
Here are some important game day tips to ensure that the party remains free of the following food safety penalties.
Illegal Use of Hands
Unclean hands are a major infraction for hosts and guests alike. Before and after preparing, handling, or eating food, always wash your hands with soap and warm water for 20 seconds. Use clean plates, dishes, and utensils to serve and restock food, and keep surfaces clean.
Offsides
To avoid this penalty, make sure raw meat and poultry do not come into contact with other foods. If they do, they can spread bacteria that cause food poisoning. Use separate plates and utensils for these items, and never place cooked food back on the same plate that previously held raw food unless the plate has first been washed in soap and warm water.
Personal Foul
Don’t risk the health of your guests by cooking meat and poultry improperly. Always use a food thermometer to make sure meat and poultry are cooked to a safe minimum internal temperature. Color is never a reliable indicator of safety and doneness. For reasons of personal preference, consumers may choose to cook meat to higher temperatures. The thermometer should be placed in the thickest part of the food and read after the manufacturer designated time.
- Cook raw beef, pork, lamb and veal steaks, chops, and roasts to 145 °F. For safety and quality, allow meat to rest for at least three minutes before carving or consuming.
- Cook raw ground beef, pork, lamb, and veal to 160 °F.
- Cook raw poultry to 165 °F.
Holding
Avoid this penalty by keeping hot food hot and cold food cold. Hot foods must have a heat source, and cold foods should be kept on ice to remain at a safe temperature and out of the Danger Zone. The Danger Zone is the temperature range between 40 °F and 140 °F where bacteria multiply rapidly.
Delay of Game
Practice effective clock management with your food. Perishable foods should not be kept at room temperature for more than two hours. Switch out these items during half time to prevent the same foods from sitting out the whole game. Perishable foods left out longer than two hours should be discarded and replenished with fresh servings.
Food safety is the winning game plan for your Super Bowl Party. By following these tips, you can defend against foodborne illness.
US measles outbreak reaching a 'critical point'
As the tally of people infected with a strain of measles traced to an amusement park in California continues to climb, health officials are warning that those who choose not to vaccinate themselves or their children will almost certainly be infected if they are exposed to the disease.
They also warn that the outbreak has not yet been contained, and some health officials are expecting the number of cases to grow.
US measles outbreak reaching a 'critical point'
Wednesday, January 28, 2015
More children get vaccinated amid measles outbreak fears - YouTube
Illinois health officials are looking into whether a case of measles can be traced to Disneyland. So far, at least 88 people in eight states have been infected. Ben Tracy reports.
Video (2:06)
More children get vaccinated amid measles outbreak fears - YouTube
Video (2:06)
More children get vaccinated amid measles outbreak fears - YouTube
Tuesday, January 27, 2015
Doctor defends parents' choice to waive measles vaccinations - YouTube
The measles outbreak that started at Disneyland grew to 87 cases in seven states. But despite the highly contagious nature of the disease, not all doctors agree that a vaccination is necessary. Ben Tracy reports.
Video (2:22)
Doctor defends parents' choice to waive measles vaccinations - YouTube
Video (2:22)
Doctor defends parents' choice to waive measles vaccinations - YouTube
First North American case of H7N9 bird flu found in Canada
Canadian health authorities say they have diagnosed a case of bird flu in a British Columbia woman who recently returned from China.
First North American case of H7N9 bird flu found in Canada
First North American case of H7N9 bird flu found in Canada
Monday, January 26, 2015
Melinda Gates has the perfect response to the anti-vaccine movement - Vox
On the heels of the measles outbreak at Disneyland, Melinda Gates of the Bill and Melinda Gates Foundation took aim at the vaccine naysayers who make these types of disease outbreaks more likely.
"We take vaccines so for granted in the United States," Gates told the Huffington Post in a prerecorded interview published on Thursday. "Women in the developing world know the power of [vaccines]. They will walk 10 kilometers in the heat with their child and line up to get a vaccine, because they have seen death. [Americans have] forgotten what measles deaths look like."
Melinda Gates has the perfect response to the anti-vaccine movement - Vox
Friday, January 23, 2015
Measles outbreak fuels vaccine debate - YouTube
The Disneyland measles outbreak is spreading and stirring a vaccine debate. CNN's Elizabeth Cohen reports on why some parents refuse to vaccinate their children.
Video (2:46)
Measles outbreak fuels vaccine debate - YouTube
Video (2:46)
Measles outbreak fuels vaccine debate - YouTube
Thursday, January 22, 2015
Are you in the 14-year gap that was unreliable for measles vaccine? - YouTube
Disneyland is offering to test its employees for measles. The move comes after an outbreak of the disease was found to have originated from its theme park. But even if you've been vaccinated before, experts say there's a troubling 14-year period where people may not have been properly vaccinated. Ben Tracy reports.
Video (2:15)
Are you in the 14-year gap that was unreliable for measles vaccine? - YouTube
Video (2:15)
Are you in the 14-year gap that was unreliable for measles vaccine? - YouTube
Wednesday, January 21, 2015
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
From Johnson and Johnson:
Brings together London School of Hygiene and Tropical Medicine, INSERM, University of Oxford University, La Centre Mura, Bavarian Nordic A/S, Vibalogics, the Grameen Foundation and World Vision of Ireland with Janssen Pharmaceutical Companies to help accelerate Ad26 – MVA Ebola vaccine development and patient education
NEW BRUNSWICK, N.J. – Jan. 16, 2015 – Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than €100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Consortia funded through the IMI Ebola+ Programme Supported by the European Commission
Brings together London School of Hygiene and Tropical Medicine, INSERM, University of Oxford University, La Centre Mura, Bavarian Nordic A/S, Vibalogics, the Grameen Foundation and World Vision of Ireland with Janssen Pharmaceutical Companies to help accelerate Ad26 – MVA Ebola vaccine development and patient education
NEW BRUNSWICK, N.J. – Jan. 16, 2015 – Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than €100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
The IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding for the IMI Ebola+ programme comes in part from Horizon 2020, the European Union’s research and innovation programme, and in part in the form of in-kind contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA) partners in the projects.
"In the face of the global challenge of Ebola, bringing together the expertise and capabilities of the pharmaceutical industry, academic centers and NGOs will be critical to help solve this crisis," said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "The European Commission's support through IMI bolsters collaboration that should significantly accelerate efforts to help address this humanitarian crisis."
"It is great to see the multiple partners come together to accelerate the development of an effective vaccine both for the current epidemic and future outbreaks," said Professor Peter Piot, M.D., director of the London School of Hygiene & Tropical Medicine, one of the consortia partners. "This is an opportunity to make sure that this is the last Ebola epidemic in which our only tools to control it are isolation and quarantine."
The funds were announced to support several consortia working together on a total of four projects. Three of the projects are designed to address the need to accelerate Phase I, II and III trials and scale up production of the prime-boost vaccine regimen. A Phase I trial led by Oxford Vaccines Group is currently underway with trials in Africa being planned. The Phase II and III trials in Europe and Africa, subject to review of the preliminary Phase I data, will be carried out in parallel. A fourth project will investigate innovative ways and technology to raise awareness and acceptance of vaccination campaigns. A total of eight projects are being funded under this round of the IMI's Ebola+ programme.
"With people still contracting this disease, there is still a risk that Ebola will continue to spread and that we could have another major outbreak in the future," said Johan Van Hoof, M.D., Global Head of Infectious Diseases and Vaccines, Janssen. "We highly appreciate the European Commission’s support and are pleased to be joined by them and our distinguished partners in further accelerating our goal of bringing this vaccine, if approved, to families and frontline health care professionals as fast as possible."
Professor Andrew Pollard and Dr Matthew Snape, who are leading the Phase I and II Ebola vaccine trials at the University of Oxford for IMI, said "the initial testing of vaccines for Ebola is already underway at the University with an astonishing response from the public to volunteer for the trials, to provide the earliest possible information to guide further studies of a prime boost vaccine, that if approved, may help control the Ebola outbreak in West Africa."
Organizations joining Janssen include the London School of Hygiene & Tropical Medicine, University of Oxford, Institut National de la Santé et de la Recherche Médicale (INSERM), La Centre Muraz, Bavarian Nordic A/S, Vibalogics, Grameen Foundation and World Vision of Ireland.
On January 6, Johnson & Johnson announced the start of a Phase I, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Johnson & Johnson also announced that Janssen, in partnership with Bavarian Nordic A/S, has produced more than 400,000 regimens of the prime-boost vaccine for use in large-scale clinical trials by April 2015. A total of 2 million regimens is projected to be available through the course of 2015, with the ability to quickly scale up to a projected 5 million regimens, if required, over a 12- to 18-month period.
In October 2014, Johnson & Johnson announced a commitment of up to $200 million to accelerate and significantly expand production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company has been seeking to share the financial risk of these vaccine and development clinical trial costs by pursuing governmental and non-governmental funding sources.
The Ebola+ programme has received funding from the Innovative Medicines Initiative 2 Joint Undertaking. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
About Janssen funded IMI Ebola+ projects and consortia members
- Topic 1: Vaccine development; in Phase I, II, and III (EBOVAC 1 & 2)
- Consortium members: Janssen,London School of Hygiene and Tropical Medicine, Oxford University, Institut National de la Santé et de la Recherche Médicale (INSERM), La Centre Muraz
- Topic 2: Manufacturing capability (EBOMAN)
- Consortium members: Janssen, Bavarian Nordic A/S, Vibalogics
- Topic 4: Deployment and compliance of vaccination regimens (EBODAC)
- Consortium members: Janssen, London School of Hygiene & Tropical Medicine, Grameen Foundation, World Vision of Ireland
Further details of the projects are available on: http://www.imi.europa.eu/
Editor’s Note: The Grant Agreements for all IMI projects involving Janssen under the first call of the Ebola+ programme are still being finalised. Final information on all selected projects, including full budget details, will be published once, and if, the Grant Agreements have been signed.
About the Ebola Vaccine Regimen
The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), uses a prime-boost combination of two components that are based on AdVac® technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, and the MVA-BN® technology from Bavarian Nordic, a biotechnology company based in Denmark.
The Crucell Holland B.V. program received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively. Preclinical experiments of the prime-boost vaccine regimen conducted by the NIH demonstrated that when either vaccines were administered two months apart, complete protection from death due to Ebola was achieved against the Kikwit Zaire strain, which is similar to the virus that is the cause of the current outbreak in West Africa. The research collaboration for a monovalent vaccine targeting the Zaire strain of the Ebola virus is part of an ongoing development program for a multivalent vaccine against all virus strains that cause disease in humans, including Ebola and Marburg viruses based on the Ad26 and Ad35 vectors.
About Johnson & Johnson
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
About Crucell
Crucell Holland B.V. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research, development and production of vaccines that prevent and/or treat infectious diseases. We have a broad development pipeline, with several product candidates based on our unique AdVac® and/or PER.C6® production technology.
Crucell Holland B.V. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research, development and production of vaccines that prevent and/or treat infectious diseases. We have a broad development pipeline, with several product candidates based on our unique AdVac® and/or PER.C6® production technology.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
Note on Forward Looking Statements
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, including regarding product development and production. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including the uncertainties of clinical success and the timeline for the availability of a potential vaccine against Ebola; the challenges and risks involved in large-scale production of a vaccine; and the uncertainty of the level of demand for a vaccine against Ebola. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)
###
Measles outbreak prompts school to keep students home - YouTube
Vaccinations almost wiped out measles. But a recent trend in vaccination waivers is believed to have contributed to a new outbreak in southern California. At least one school is now telling certain students to stay home as a way to prevent the outbreak from spreading. Ben Tracy reports.
Video (2:10)
Measles outbreak prompts school to keep students home - YouTube
Video (2:10)
Measles outbreak prompts school to keep students home - YouTube
Saturday, January 17, 2015
Morning Rounds: Flu shot falls short - YouTube
CBS News chief medical correspondent Dr. Jon LaPook and CBS News medical contributor Dr. Holly Phillips weigh in on the efficacy of the flu vaccine and the shortage of a life-saving device.
Video (7:48)
Morning Rounds: Flu shot falls short - YouTube
Video (7:48)
Morning Rounds: Flu shot falls short - YouTube
Friday, January 16, 2015
KC children's hospital reports 2 flu deaths | Local News - KMBC Home
Two pediatric flu deaths have been reported in Kansas City, according to Children's Mercy Hospital.
KC children's hospital reports 2 flu deaths | Local News - KMBC Home
KC children's hospital reports 2 flu deaths | Local News - KMBC Home
Flu vaccine not working well; only 23 percent effective - KCTV5
The poor showing is primarily because the vaccine doesn't include the bug that is making most people sick, health officials say. In the last decade, flu vaccines at their best were 50 to 60 percent effective.
Read more: http://www.kctv5.com/story/27860070/flu-vaccine-not-working-well-only-23-percent-effective#ixzz3P04NZ4Ho
Flu vaccine not working well; only 23 percent effective - KCTV5
Wednesday, January 14, 2015
Monday, January 12, 2015
Sunday, January 11, 2015
Nearly half of South Florida hospitals below CDC standards on infections | The Miami Herald
More than 40 percent of South Florida hospitals fell below national standards for preventing certain types of common infections in their patients in 2013, according to federal data.
At the same time, 56 percent of local hospitals performed better than expected in controlling infections, according to the same data, information that South Florida consumers could use when choosing a hospital.
Nearly half of South Florida hospitals below CDC standards on infections | The Miami Herald
Friday, January 9, 2015
Thursday, January 8, 2015
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
From Johnson & Johnson:
NEW BRUNSWICK, N.J. – Jan. 6, 2015 – Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015
NEW BRUNSWICK, N.J. – Jan. 6, 2015 – Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
Johnson & Johnson also announced today that Janssen, in partnership with Bavarian Nordic A/S, has produced more than 400,000 regimens of the prime-boost vaccine for use in large-scale clinical trials by April 2015. A total of 2 million regimens will be available through the course of 2015, with the ability to quickly scale up to 5 million regimens, if required, over a 12- to 18-month period. This increased projection is an update to Janssen’s previous goal of producing more than 1 million regimens by the end of 2015, with 250,000 regimens for broad application in clinical trials by May 2015.
“As a leader in the field of global health, we have a responsibility to act swiftly as Ebola continues to cause suffering among patients, families and health care workers in West Africa,” said Alex Gorsky, Chairman and CEO of Johnson & Johnson.
Modelling by the London School of Hygiene and Tropical Medicine to advise the World Health Organization (WHO) indicates that to bring the epidemic under control, current projected demand for a preventive vaccine ranges from a minimum of 100,000 doses to protect frontline workers to a high-end of 12 million doses for large-scale adult vaccination in the three affected countries.
“Because every day counts, we are substantially accelerating the production of our vaccine regimen,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Through the unprecedented collaboration among the global health community, our goal is to bring this vaccine to families and frontline health care professionals as fast as possible.”
The Phase 1, first-in-human study will evaluate the safety and tolerability of a prime-boost vaccine regimen, in which patients are first given a dose to prime the immune system, and then a boost intended to enhance the immune response over time. The immune response generated by the regimen will also be evaluated longer term. Different regimens combining the vaccine components or placebo will be studied in 72 healthy adult volunteers. Additional clinical studies are planned to begin in the United States later this month and soon after in Africa. Further details of the study are posted on clinicaltrials.gov.
“We’ve been working at an unprecedented pace together with our partners to significantly accelerate our efforts,” said Dr. Matthew Snape of the Oxford Vaccine Group and the study leader. “Initiating this study in the space of eight weeks represents a critical leap forward in being able to rapidly develop an Ebola prime-boost vaccine regimen, and these results will be vital to the design of future studies in broader populations.”
In October 2014, Johnson & Johnson announced a commitment of up to $200 million to accelerate and significantly expand production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is seeking to share the financial risk of these vaccine and development clinical trial costs by pursuing governmental and non-governmental funding sources. The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health (NIH), uses a prime-boost combination of two components that are based on AdVac® technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, and the MVA-BN® technology from Bavarian Nordic, a biotechnology company based in Denmark.
The Crucell Holland B.V. program received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively. Preclinical experiments of the prime-boost vaccine regimen conducted by the NIH demonstrated that when both vaccines were administered two months apart, complete protection from death due to Ebola was achieved against the Kikwit Zaire strain, which is similar to the virus that is the cause of the current outbreak in West Africa. The research collaboration for a monovalent vaccine targeting the Zaire strain of the Ebola virus is part of an ongoing development program for a multivalent vaccine against all virus strains that cause disease in humans, including Ebola and Marburg viruses based on the Ad26 and Ad35 vectors.
The Johnson & Johnson Family of Companies continues to closely collaborate with WHO, NIAID and the European Commission, as well as other key stakeholders, governments, public health authorities, and non-governmental organizations on the clinical testing, development, production and distribution of the vaccine.
The effects of Ebola in West Africa continue to significantly strain the health care systems of Liberia, Sierra Leone and Guinea. Johnson & Johnson disaster response efforts continue through its support of Direct Relief International, Partners in Health, AmeriCares, IntraHealth and Project HOPE. The company also supports the ongoing efforts by public health authorities, including the U.S. Centers for Disease Control and Prevention and WHO, to mount a coordinated world response to address the immediate needs raised by the Ebola outbreak. As part of its commitment to support nurses, Johnson & Johnson gave an educational grant to Nurse.com to make available to every nurse in the U.S. continuing education resources about Ebola.
About The Phase 1, First-in-Human Study of Heterologous Prime-Boost Ebola Vaccine Regimens
The volunteers in this study will be enrolled into four groups and randomized to receive either active vaccine or placebo. Those getting an active dose will receive a prime vaccination in one of four regimens according to randomization on day one and then receive the boost component either one or two months apart, depending on which group they are in. Analyses of these regimens will inform decisions for future studies, such as the order in which the two components should be given and how closely together they can be given to ensure the optimal protection and sustainability. Further details of the study are posted on clinicaltrials.gov.
About Johnson & Johnson
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
About Crucell
Crucell Holland B.V. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research, development and production of vaccines that prevent and/or treat infectious diseases. We have a broad development pipeline, with several product candidates based on our unique AdVac® and/or PER.C6® production technology.
Crucell Holland B.V. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and is focused on research, development and production of vaccines that prevent and/or treat infectious diseases. We have a broad development pipeline, with several product candidates based on our unique AdVac® and/or PER.C6® production technology.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.
Note on Forward Looking Statements
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, including regarding product development and production. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including the uncertainties of clinical success and the timeline for the availability of a potential vaccine against Ebola; the challenges and risks involved in large-scale production of a vaccine; and the uncertainty of the level of demand for a vaccine against Ebola. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)
###
Wednesday, January 7, 2015
Tuesday, January 6, 2015
Sunday, January 4, 2015
American exposed to Ebola headed to Nebraska | Health - KMBC Home
January 4, 2015
An American health care provider working in Sierra Leone who had a "high-risk exposure" to Ebola will arrive at Nebraska Medicine on Sunday, the center said.
American exposed to Ebola headed to Nebraska | Health - KMBC Home
An American health care provider working in Sierra Leone who had a "high-risk exposure" to Ebola will arrive at Nebraska Medicine on Sunday, the center said.
American exposed to Ebola headed to Nebraska | Health - KMBC Home
Subscribe to:
Comments (Atom)